Britany Sasser
Family · Dothan, ALNPI 1275100737
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 252 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by GSK at 24.2% of the total. Reporting peaked in 2022 at $2,305 and has fallen 84.6% since, to $356 in 2025. Among family clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 252 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$815
- Boehringer Ingelheim$714
- Amgen$249
- Regeneron Healthcare Solutions, Inc.$229
- Actelion Pharmaceuticals US, Inc.$224
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,809100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 68 | $1,166 |
| AstraZeneca(2 entities) | 41 | $815 |
| Boehringer Ingelheim | 31 | $714 |
| Amgen | 13 | $249 |
| Regeneron Healthcare Solutions, Inc. | 11 | $229 |
| Actelion Pharmaceuticals US, Inc. | 10 | $224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $183 |
| Grifols USA, LLC | 9 | $178 |
| Mylan Specialty L.p. | 9 | $171 |
| United Therapeutics Corporation | 5 | $165 |
| Electromed, Inc. | 13 | $156 |
| Johnson & Johnson(2 entities) | 4 | $79 |
| Medtronic | 1 | $59 |
| Inogen, Inc. | 5 | $46 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Sanofi | 2 | $44 |
| Insmed, Inc. | 2 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| AbbVie | 2 | $35 |
| Merck | 2 | $26 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Harmony Biosciences LLC | 2 | $22 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,809 in reported general payments places this provider in the 90th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $142,735 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 139 | $97,399 |
| MounjaroTirzepatide | 62 | $68,573 |
| FarxigaDapagliflozin Propanediol | 72 | $61,679 |
| OzempicSemaglutide | 38 | $37,254 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $17,863 |
| TrulicityDulaglutide | 11 | $10,810 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $9,958 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,974 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 86 | $1,692 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,324 |
| Doxycycline Hyclate | 129 | $1,269 |
| Atorvastatin Calcium | 116 | $1,130 |
| Esomeprazole Magnesium | 16 | $972 |
| Montelukast Sodium | 75 | $831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $183 | $142,73513 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,166 | $107,356162 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $815 | $82,516107 claims |
| Novo NordiskOzempic | $15 | $37,25438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,415 family providers in Alabama.
Other family in Dothan
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
- Julia BettsHuntsville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.